Literature DB >> 6722739

Exogenous estrogen and breast cancer after bilateral oophorectomy.

R A Hiatt, R Bawol, G D Friedman, R Hoover.   

Abstract

Estrogen use in 119 women in whom breast cancer developed after surgically induced menopause was compared to use among an equal number of controls matched for age, date of bilateral oophorectomy, and duration of follow-up. No increased risk for estrogen use versus no use was evident (relative risk = 0.7). When the authors examined three measures of estrogen dose--number of chart notations of estrogen use, time since first use, and duration between first and last use--only those with greater than or equal to 5 notations had any significantly elevated risk (relative risk = 2.1; confidence limits 1.2-3.6), and there was a significant trend toward increasing risk with more notations (P = 0.03). Use specifically of conjugated estrogens was also associated with an increasing risk with more notation of estrogen use (P = 0.07). However, the other two measures of dose did not confirm this trend. Matched multiple logistic analysis suggested that number of notations of estrogen use conferred increased breast cancer risk (relative risk = 1.7), in dose-response relationships, but this result could have occurred by chance. Because of a lack of consistency, the generally low and statistically nonsignificant relative risks, and the lack of consistent effect modification in high-risk groups, the authors were unable to demonstrate a clear increased risk of breast cancer associated with replacement estrogen use.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722739     DOI: 10.1002/1097-0142(19840701)54:1<139::aid-cncr2820540128>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Noncontraceptive hormone use and risk of breast cancer.

Authors:  C P Yang; J R Daling; P R Band; R P Gallagher; E White; N S Weiss
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 2.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 3.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 4.  Hormone replacement therapy and breast cancer. A review of current knowledge.

Authors:  L Bergkvist; I Persson
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 5.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

Review 6.  That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention.

Authors:  T G Palferman
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

Review 7.  Sex steroids and cancer in older women.

Authors:  T R Varma
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

8.  Family history of malignancies and risk of breast cancer: prospective data from the Shanghai women's health study.

Authors:  Briseis A Kilfoy; Yawei Zhang; Xiao-Ou Shu; Yu-Tang Gao; Bu-Tian Ji; Gong Yang; Hong Lan Li; Nathaniel Rothman; Wong-Ho Chow; Wei Zheng
Journal:  Cancer Causes Control       Date:  2008-06-25       Impact factor: 2.506

Review 9.  Estrogen replacement therapy (ERT) in high-risk cancer patients.

Authors:  K A Hutchinson-Williams; J N Gutmann
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec

10.  Menopausal oestrogens and breast cancer risk: an expanded case-control study.

Authors:  L A Brinton; R Hoover; J F Fraumeni
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.